Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(42)
Filter by content year
(-)
2022
(42)
Filter by form group
Filter by category
(-)
Clinical
(42)
Collaborators
(37)
All
(34)
Other
(17)
Science
(10)
Events
(2)
Filter by category
Search
News
Pfizer und BioNTech beginnen Phase-1-Studie mit Einzeldosis eines kombinierten mRNA-Impfstoffkandidaten gegen Influenza und COVID-19
News
Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19
News
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
News
Pfizer und BioNTech veröffentlichen weitere klinische Daten zu an Omikron BA.4/BA.5 angepassten Auffrischungsimpfstoff mit deutlich stärkeren Immunantworten in Erwachsenen im Vergleich zum ursprünglichen COVID-19-Impfstoff
News
Positive Phase-1-Daten von mRNA-basierter individualisierter Neoantigen-spezifischer Immuntherapie bei Patienten mit Bauchspeicheldrüsenkrebs auf ASCO vorgestellt
News
Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO
News
Pfizer und BioNTech geben hohe Immunantwort von Omikron-angepassten COVID-19-Impfstoffkandidaten gegen Omikron bekannt
News
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
News
Pfizer und BioNTech geben hohe Immunantwort von Omikron-angepassten COVID-19-Impfstoffkandidaten gegen Omikron bekannt
News
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
Pagination
Previous page
‹‹
Page 2
Next page
››